Loading...
Bilateral Trade Intelligence · $12 Total Trade · 1 Foreign Suppliers · 1 Indian Buyers · DGFT Verified · Updated March 2026
India imported $12 worth of pharmaceutical formulations from Bhutan across 1 verified shipments, from 1 foreign suppliers to 1 Indian buyers. The top suppliers are ROYAL GOVERNMENT OF BHUTAN ($12). The leading products are Serum ($12). Average shipment value: $12.
| # | Formulation | Value | Share |
|---|---|---|---|
| 1 | Serum | $12 | 100.0% |
India imports 1+ pharmaceutical formulations from Bhutan with a combined trade value of $12. Key products include Serum ($12). These are finished dosage forms — tablets, capsules, injectables, and combination drugs — shipped from Indian manufacturing facilities with FDA, WHO-GMP, and EU GMP certifications. Data from 1 verified Indian Customs (DGFT) shipment records.
These are the top pharmaceutical products exported from India to Bhutan, each with a dedicated trade route analysis page. Click any product to see detailed export data including Indian suppliers, Bhutan buyers, regulatory requirements, and logistics for that specific product corridor. Products include Serum ($12) — all finished pharmaceutical formulations verified from Indian Customs (DGFT) records.
1 Indian pharmaceutical companies export finished formulations to Bhutan. Leading exporters include Royal Government Of Bhutan, . The top exporter accounts for 100.0% of total India–Bhutan pharma exports. Source: Indian Customs (DGFT).
1 companies in Bhutan import pharmaceutical formulations from India. Top buyers include Diplomatic personnel, Counsellor officers in India, . The largest buyer accounts for 100.0% of India–Bhutan pharma imports. Source: Indian Customs (DGFT).
Historical evolution, India's market position, and recent developments
The pharmaceutical trade corridor between Bhutan and India has remained relatively modest over the years. Between 2022 and 2026, India imported a total of $12 worth of finished pharmaceutical formulations from Bhutan, comprising a single shipment of serum. This limited trade volume underscores the nascent stage of this bilateral pharmaceutical exchange. Historically, Bhutan's pharmaceutical exports to India have been minimal, with the 2022 shipment marking a significant, albeit isolated, event in this trade relationship.
Bhutan's contribution to India's pharmaceutical imports is negligible, accounting for a mere $12 in 2022. The sole product imported was serum, indicating that Bhutan's pharmaceutical exports to India are currently limited to specific, perhaps niche, products. This suggests that Bhutan does not play a significant role in India's broader pharmaceutical import landscape.
Between 2024 and 2026, there have been no notable policy changes, trade agreements, or regulatory harmonization efforts between Bhutan and India concerning pharmaceutical imports. The absence of such developments reflects the limited scope of the pharmaceutical trade between the two nations during this period.
Registration process, GMP requirements, import documentation
For Bhutanese companies to import pharmaceutical products into India, they must navigate the Central Drugs Standard Control Organization (CDSCO) registration process. This involves submitting an application in Form 40 or 41, depending on the product type, along with comprehensive documentation, including a Certificate of Pharmaceutical Product (CoPP) from the country of origin, a Good Manufacturing Practices (GMP) certificate, and a Drug Master File (DMF). The timeline for this process can vary, but it typically spans several months, depending on the completeness and accuracy of the submitted documentation. Clinical trial waivers may be granted for certain products, particularly if they are already approved in other major markets.
India requires that pharmaceutical products imported from Bhutan adhere to Good Manufacturing Practices (GMP) standards. Bhutanese manufacturing sites must obtain GMP certification from the Bhutan Food and Drug Authority (BFDA), which is recognized by the World Health Organization (WHO). The CDSCO may conduct inspections to verify compliance with these standards, ensuring that imported products meet India's quality and safety requirements.
Importing pharmaceutical products into India necessitates obtaining an import license (Form 10) from the Directorate General of Foreign Trade (DGFT). Additionally, a registration certificate from the CDSCO is required, along with a No Objection Certificate (NOC) from the Market Authorization Holder, if applicable. A test license may also be necessary, depending on the product type. Customs procedures involve submitting these documents to Indian customs authorities for clearance, ensuring that all regulatory requirements are met before the products enter the Indian market.
Dominant categories, emerging opportunities, and demand drivers
The pharmaceutical imports from Bhutan to India are currently limited to a single product category: serum. This indicates that India's pharmaceutical imports from Bhutan are concentrated in specific, perhaps specialized, product types. The absence of a diverse range of products suggests that Bhutan's pharmaceutical export capabilities to India are still in the developmental stages.
Given the limited volume and variety of pharmaceutical imports from Bhutan to India, there is currently no significant presence of innovator drugs, novel formulations, or advanced therapies in this trade corridor. The focus remains on basic pharmaceutical products, such as serum, with no notable imports of specialized or innovative pharmaceutical products from Bhutan to India.
The minimal pharmaceutical imports from Bhutan to India can be attributed to several factors:
Tariff structure, trade agreements, IP and patent landscape
Pharmaceutical formulations imported into India are subject to the Most Favored Nation (MFN) tariff rates, which include basic customs duty, Integrated Goods and Services Tax (IGST), and health cess. The exact rates can vary and are subject to periodic revisions by the Indian government. Importers must stay updated on these rates to ensure compliance and accurate cost calculations.
As of March 2026, there are no specific Free Trade Agreements (FTAs) or preferential duty rates between India and Bhutan concerning pharmaceutical imports. Both countries are members of the Regional Comprehensive Economic Partnership (RCEP), but the impact of this agreement on pharmaceutical trade between India and Bhutan remains limited due to the minimal trade volume.
India's patent regime, particularly Section 3(d) of the Indian Patents Act, aims to prevent evergreening of patents and ensures that only genuine innovations are patented. Compulsory licensing provisions allow the government to grant licenses to third parties to produce patented products under certain conditions, such as public health emergencies. The National Pharmaceutical Pricing Authority (NPPA) regulates the prices of essential drugs, including imported ones, to ensure affordability and accessibility.
Shipping routes, port infrastructure, cold chain compliance
Pharmaceutical products imported from Bhutan to India are likely transported by road, given the geographical proximity and the limited volume of trade. The transit time is relatively short, typically ranging from a few days to a week, depending on the specific origin and destination points. The reliability of these routes is generally high, with established infrastructure facilitating smooth transportation.
Given the limited volume of pharmaceutical imports from Bhutan to India, specific data on Bhutanese export ports and Indian import ports handling these shipments is not readily available. However, major Indian ports such as Kolkata and Guwahati are likely to handle such imports, given their proximity to Bhutan and established trade routes.
Pharmaceutical imports into India undergo customs clearance procedures, which include verification of import licenses, registration certificates, and other necessary documentation. The Central Drugs Standard Control Organization (CDSCO) may conduct testing of imported pharmaceutical products to ensure compliance with Indian standards. Cold chain management is critical for certain pharmaceutical products, and importers must ensure that their logistics partners adhere to Good Distribution Practices (GDP) to maintain product integrity during transit.
Market size, healthcare system, growth outlook
Despite being a major pharmaceutical manufacturer, India imports certain pharmaceutical products from Bhutan due to factors such as patent protection, technology gaps, and specific quality requirements. The limited volume of imports suggests that these factors are currently not significant drivers of import dependency.
As of March 2026, there are no major Bhutanese pharmaceutical companies supplying products to India. The pharmaceutical trade between the two countries is minimal, and Bhutanese companies have yet to establish a significant presence in the Indian market.
India's Atmanirbhar Bharat initiative and the Production Linked Incentive (PLI) scheme aim to boost domestic manufacturing and reduce import dependency. These policies may impact the future growth of pharmaceutical imports from Bhutan, potentially leading to a decline or substitution of imports as India strengthens its self-reliance in pharmaceutical production.
Competing origins, India's edge, challenges and threats
India imports pharmaceutical products from various countries, including the USA, EU, China, Switzerland, and Japan. Bhutan's share in this competitive landscape is negligible, given the minimal trade volume. The dominance of established pharmaceutical exporters makes it challenging for Bhutan to gain a foothold in the Indian market.
While Bhutan may offer advantages such as proximity to India and potentially lower transportation costs, these factors are currently outweighed by the limited scale and diversity of its pharmaceutical exports. The lack of significant innovation, brand recognition, and established distribution networks further diminishes Bhutan's competitive edge in the Indian pharmaceutical market.
Indian pharmaceutical manufacturers are continually developing alternatives to imported products, including biosimilars and generics. The government's PLI-backed capacity expansion further strengthens domestic production capabilities, posing a threat to the growth of pharmaceutical imports from Bhutan. The emphasis on self-reliance and cost competitiveness may lead to a reduction in the demand for imported pharmaceutical products.
India exported pharmaceuticals worth $12 to Bhutan across 1 verified shipments.
1. ROYAL GOVERNMENT OF BHUTAN — $12. Total: 1 suppliers.
1. Diplomatic personnel, Counsellor officers in India — $12. 1 buyers total.
1. Serum ($12, 100.0%)
Export: . Import: .
India's cost-competitive generic drug manufacturing, WHO-GMP certified facilities, and broad product portfolio. This $12 corridor reflects quality compliance and pricing advantages.
WHO-GMP certification, EU GMP approval (for EU markets), product dossier registration (CTD format), and ICH guideline compliance.
$12 per consignment across 1 shipments.
1 Indian companies. Largest: ROYAL GOVERNMENT OF BHUTAN with $12.
TransData Nexus covers 1 active exporters with shipment history and trade values at transdatanexus.com.
Access complete shipment records, supplier intelligence, buyer histories, and price analytics for all 1 shipments.
Data sourced from Indian Customs (DGFT) records. Verify regulatory status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1 Exporters
1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists